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ABSTRACT
There are puzzle pieces to the cure for Alzheimer’s Disease and such can be found by
inspecting the biomolecular interactions and their effects on neuronal cells. The upcoming
presented literature review will cover the molecular changes caused in Alzheimer’s Disease
pathological progression, explore the relationship between non-Alzheimer’s Disease molecules
and Alzheimer’s Disease molecules in the body, and analyze potential contributing factors in
Alzheimer’s Disease. In addition, the information that will be provided will highlight medicinal
alternatives respective to a particular stage in Alzheimer’s. If interventions are found at each key
player step in Alzheimer’s—such as Aβ plaque formation, tau protein aggregates, loss of
synaptic transmission, and neuroinflammatory responses—then the progression of the disease
can be halted. Additionally, if the Amyloid Precursor Protein is not cleaved, this disease can
potentially be stopped entirely because the plaques will be eradicated as well as the tau proteins;
there will be no neuroinflammatory responses in the brain.
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Chapter 1: Introduction
Alzheimer’s Disease Outlook
Alzheimer’s Disease is classified as the sixth leading cause of death for all adults and is
the most abundant type of dementia [1]. This disease affects more than 25 million individuals
worldwide [2]. By the year 2050, this disease is expected to impact 13.8 million individuals in
the United States over the age of 65 [3]. The neurodegenerative disease causes progressive
cerebral death and loss of function respective to the region of the brain it affects. In the
beginning stages of AD, the usual symptoms relate to the loss of memory but as the disease
progresses, symptoms such as—anxiety, anger, petulance, depression, insomnia, and delusions
emerge [4]. Emotional dysregulation such as symptoms of euphoria is also characterized in this
stage of AD [5]. As the disease progresses individuals require assistance with performing their
daily tasks and become more reliant on others. In the preclinical stage of AD, there are no
symptoms. Biomarkers at this stage include testing positive for ApoE4, elevated levels of tau
protein in the cerebrospinal fluid (CSF), increased thickness of the right entorhinal cortex,
increased volume of the right hippocampus, and low amyloid concentration [4, 6]. In the mild
stage of AD memory loss and language problems become evident. Due to the mild cognitive
impairment, individuals can still function on a normal basis, stay in their workplace, and remain
social. Unfortunately, at this stage, with each year that passes 10% progression of the disease is
observed [4]. Dementia is the last stage of AD, up to 40% of individuals will experience
delusions, the sleep-wake cycle becomes disrupted, language and speech become compromised,
visuospatial skills become compromised and individuals become lost in their surroundings [4].
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1.1 APoE increases the risk of Alzheimer’s Disease
The apolipoprotein APoE—has been shown to increase the risk for developing AD. A
non-carrier of the APoE gene has an AD frequency of 20%. Being heterozygous for one copy of
the APoE gene increases the chances of developing AD by 47% and inheriting two copies of the
APoE has an AD frequency of 91% [7]. Apolipoproteins bind to receptors on the surface of cells
and activate enzymes. The apolipoproteins also bind to lipoprotein receptor-related protein 1
(LRP-1), very low-density LDL receptor (VLDL-R), Low-density lipoprotein-receptor (LDL-R),
ApoE receptor 2 (apoER2), and megalin/gp330 [8]. Lipoproteins, such as LDL, bind to
hepatocytes for B-oxidation and recycling as triacylglycerol (TAG). Lipoprotein lipase helps to
deliver lipoprotein particles inside of the cells. Researchers have found that mutations in
lipoprotein lipase increase the risk of developing AD [9]. Isoform differences in apolipoproteins
show that Cysteine is replaced by an Arginine in the 112th amino acid for APoE, contributing to
AD pathology [10].
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METHODOLOGY
This literature review firstly provided background information on neuronal anatomy and
physiology in order to expand on the molecular knowledge of Alzheimer’s Disease. Upon
establishing this knowledge, the creation of tau pathologies, amyloid abnormalities, and neuronal
apoptosis was explored via molecular biology interactions. After presenting the interactions that
led to abnormalities seen in Alzheimer’s Disease, the next step was to provide therapeutic
treatments that combat each stage of AD per contributing interactions previously mentioned at
the beginning of this review. Upon assessing the scientific validity of the molecular interactions
that contributed to AD, associations between the potential channels by which they occurred were
explored. I aimed to find therapeutic treatments related to the sections that composed the
beginning of this review. For instance, I mentioned the importance of the cholinergic system in
AD in chapter 3.5; correspondingly, chapter 12.1 discussed a therapeutic intervention related to
the cholinergic system. In chapter 2.4 I discussed how the formation of Aβ plaques took place,
consequently in chapters 7.1-7.5 discussed various antibody therapeutic interventions that
targeted these plaques. In chapter 2.2 I suggested that therapeutic treatments to target the
activation loop of the kinase enzyme could result beneficial in treating AD. Consequently, I
listed in chapter 9.1 the drug DNL104, still under clinical trial, and targets the activation loop,
which has been shown to reduce neuroinflammatory responses in AD. Additionally, the stage of
Alzheimer’s Disease treated by these drugs was provided to identify the best treatment option per
progression of this disease. While some of these drugs have been approved for usage by the
FDA, it is to note that some drugs are still under clinical trial, thereby, more testing is
encouraged to determine their therapeutic effectiveness.
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Chapter 2: Alzheimer’s Disease and Related Pathological Neurobiology
2.1 Neurobiological Makeup
Alzheimer’s Disease (AD) is characterized by loss in cerebral function as neurons begin
to die. The neurons in the brain are essential for sending and receiving signals to and from each
cerebral lobe. A neuron is composed of a cell body, dendrite, and axon [11]. Contained within
the neuron there is a cell body that retains the nucleus; responsible for regulating the cellular
activity [11]. The dendrites branch out from the cell body and receive information from nearby
neurons. The axon relies on the message from the neuron to other neurons and is shaped like a
cable cord [12]. On top of each axon, there is a myelin sheet, responsible for providing insulation
to the axon; increased myelination leads to a faster action potential signal transmission, thus
messages are received and sent quicker [13]. In Alzheimer’s Disease, the communication
between neurons is damaged, which leads to clinical symptoms observed in the affected region
of the brain. Typically, the first area of the brain to be damaged is the entorhinal complex
followed by the hippocampus and later on the cerebral cortex [12, 14]. The entorhinal cortex is
important for memory formation, such as recognizing patterns and has been observed to be
damaged in the early stages of AD [14]. The hippocampus is important for the recollection of
memory, called episodic/declarative memory which involves recalling facts and events [15]. It
has also been noted that the hippocampus regulates the response to emotions and carries these
signals to the mamillary bodies and relayed to the gyrus [15]. Long-term memory formation and
spatial navigation are important roles of the hippocampus. Damage to the hippocampus has been
observed to lead to disorientation, loss of new declarative memories, and leads to problems such
as the inability to hold conversations [16]. The cerebral cortex is responsible for regulating
2

language, thought processes, emotions, reason, and memory [17]. In Alzheimer’s Disease these
processes are seen to decline as neurons begin to die and the signals become interrupted.

Figure 1. The makeup of a Neuron.
Neurons have a cytoskeleton which is composed of actin filaments, intermediate
filaments, and microtubules [18]. Dendrites and axons (neurites) contain microtubules inside of
them, bundles of tube-like structures, such are responsible for maintaining the integrity and
growth of the neurites [19]. A microtubule is composed of tubulin dimers (alpha and β tubulin),
tubulin is a globular protein, which collectively forms its structure [20]. The dendrites in a
neuron contain organelles such as mitochondria, polyribosomes, etc. which are transported from
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the body of the neuron to the axon to ensure their survival, this transportation depends on
microtubules [19].

Figure 2. Shows the components inside of an axon and dendrite, the relevance of tau proteins in
the microtubules of axons, and related molecules in dendrites.

As shown in Figure 2, the microtubules contained inside of the axons are attached by tau
proteins and the microtubules of the dendrites are able to maintain their integrity by their
attachment to the microtubule-associated protein 2 (MAP2) [19]. MAP2 and tau are
phosphoproteins; both are regulated by phosphorylation [21]. In Alzheimer’s Disease, the tau
proteins that are attached to the microtubule inside of the axons become detached from the
microtubules and, instead, attach to other tau proteins, thus leading to the formation of
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neurofibrillary tangles (NFT) within the neuron. Neurofibrillary tangles interrupt the crosstalk of
neurons at the synaptic cleft and thus lead to neurodegeneration [21]. These neurodegenerative
changes are attributed to the hyperphosphorylation of the tau proteins as well as a
posttranslational modification in microtubules called polyglutamylation. A normal tau protein
contains 2-3 moles of phosphate per mole of itself, this allows for the adhesion of tau to tubulin
and further polymerization into a microtubule [21]. However, in a diseased AD brain more
phosphate groups are added to the tau protein via hyperphosphorylation and thus the microtubule
assembly becomes compromised which results in neurodegeneration. Additionally, the posttranslational addition of glutamate groups, polyglutamylation, onto microtubules causes changes
in the axons of a neuron, interrupting transportation processes [22]. Mouse studies have shown
that when polyglutamylation is halted, so does neurodegeneration [22]. Human studies have
shown similar neurodegenerative patterns involving the polyglutamylation of microtubules.
Researchers studied thirteen patients suffering from infantile-onset neurodegeneration and
discovered their cause to be attributed to polyglutamylation dysfunction alongside a loss in
CCP1 deglutamylation [23]. CCP1 is a tubulin deglutamylase responsible for the transportation
of mitochondria. Loss in CCP1 has proven fatal to neurons of the Purkinje cell, these cells are
located in the cortex of the cerebellum (which regulates motor movement) [24]. Thus, for
cerebellum neurons to be maintained healthy, CCP1 must be preserved. In addition, finding
methods to prevent the hyperphosphorylation of tau proteins can contribute to maintaining
neuronal health and decreasing the likelihood of AD.
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2.2 Kinases contribution to Tau Pathology
Phosphorylation is a process that adds phosphates, primarily from adenosine triphosphate
(ATP), onto an amino acid [25]. There are 20 amino acids that constitute the basis of reactions in
our body, out of which only 3—serine, threonine, and tyrosine—can participate in
phosphorylation [26]. Kinases are proteins that transfer a phosphate group onto the amino acids
serine, threonine, and tyrosine [27]. Kinases that have the ability to phosphorylate serine and
threonine have been named serine-threonine kinases. Tyrosine kinases are able to add a
phosphate group on tyrosine’s. The tau protein in AD contains a serine 202 residue and a
threonine 205 residue, which are accessible for phosphorylation [28]. Phosphorylation of a
protein, at their serine, threonine, or tyrosine residues, tags the protein for recognition by other
proteins [29]. When these proteins bind, they cause signal transduction to the cell; consequently
may cause cell apoptosis, cell proliferation, or cellular movement [25].
Hyperphosphorylation, excessive phosphorylation, of proteins has been linked to disease
formation. In Alzheimer’s Disease, the tau protein becomes hyperphosphorylated which
contributes to neurofibrillary tangle formation [21]. The kinase enzyme has a binding pocket for
ATP from which a phosphate group is transferred onto serine, threonine, and tyrosine. The
amino acids that make up the kinase enzyme have distinct roles for constituting the kinase
activity such as—ATP binding, substrate binding, and transfer of phosphate group
(phosphotransfer) [30, 31]. The activation loop of a kinase enzyme recognizes—tyrosine, serine,
and threonines [32].
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Thus, I suggest that researchers focus on ways to inhibit the activation loop of kinases to
prevent the recognition of these amino residues in tau proteins and thus extinguish
hyperphosphorylation activity. The YRD motif, also known as the HRD motif, requires the
amino acid aspartate to transport the gamma phosphate on ATP (ATP triphosphate consists of
alpha, beta, and gamma phosphate) onto a serine, threonine, or tyrosine amino acid [33]. Without
the presence of aspartate, even if the kinase binds to an ATP molecule, it will not be able to
perform phosphorylation [33]. Thus, finding methods to prevent aspartate binding at the HRD
motif can stop kinase activity and thus reduce tau pathology in AD.

2.3 Phosphate Contribution in AD via PP2A
Inversely to inhibiting kinase activity to reduce AD pathology, activating the phosphatase
domain may result in more efficiency at achieving the same goal [34]. A phosphatase is
responsible for the removal of a phosphate group from an amino acid. The phosphoprotein
phosphatase 2A (PP2A) is responsible for 70% of the dephosphorylating activity involving tau
proteins [35]. It has been observed that PP2A interaction with tau is greatly diminished in AD
[36]. PP2A utilizes its beta subunits, in a regulatory manner, to interact with specific substrates
and prevents the indiscriminate binding to other substrates which may affect its phosphatase
activity [37]. Increasing PP2A activity is beneficial in AD because it would decrease tau
hyperphosphorylation as its main job is to remove phosphate groups from the tau molecule [38].
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2.4 Process of Aβ Plaques Formation in AD

Figure 3. Explains the process of the creation of non-amyloidogenic vs. amyloidogenic APP
processing.
Amyloid precursor protein (APP) is synthesized in the Endoplasmic Reticulum (ER),
transported via the Trans Golgi Network (TGN), and delivered to the plasma membrane [39]. In
amyloidogenic APP processing, APP is cleaved by a β-secretase (BACE-1 is the primary βsecretase in the brain) [40] and leads to the formation of a C-terminal fragment that is 99 amino
acids in length (CTF 99) [41]. When CTF 99 is cleaved by gamma-secretase this forms an APP
intracellular domain (AICD) molecule that stays in the cytoplasm and an Aβ fragment
which is released to the extracellular part [41]. known aggregates of this Aβ cause Aβ plaque
aggregations that disrupt neuronal communication and result in neurotoxicity [42].

8

However, in non-amyloidogenic APP processing, cleavage of APP by alpha-secretase
does not result in amyloidogenic plaques. Alpha-secretase cleaves APP into a soluble APP alpha
(sAPPα) and a C-terminal fragment that is 83 amino acids long (CTF 83) [41]. sAPPα exits into
the extracellular space while CTF83 stays in the cytoplasm [41]. A gamma-secretase cleaves
CTF 83 into an APP intracellular domain, which stays in the cytoplasm, and a P3 molecule that
is exported to the extracellular space [41]. Thus, cleavage does not promote an amyloidogenic
path.
There are different amyloid isoforms due to cleavage of APP by γ-secretase, which
creates diversity in the C-terminal fragment [43]. The most abundant isoform of amyloid is Aβ
(1-40); constitutes 80-90% of all amyloid [43, 44]. The next but least abundant fragment
(constituting 5-10% of amyloids) is Aβ (1-42), however, due to its hydrophobic properties and
ability to create fibrils, these are deposited in the brain, and found to be particularly neurotoxic in
AD [43, 44]. Aβ (1-42) has been observed to result in reactive oxygen species (ROS) that
contribute to the neurodegeneration observed in AD [45]. It is to note, that the C-terminal
fragment CTF99, can cleave APP into fragments that also result in the following Aβ: 43,45,
46,48, 49, and 51[46, 47].
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2.5 Modified Formation of Lipid Rafts in AD leads to Aβ plaque Formation
Studies have found that low-density lipoprotein (LDL) is more oxidized in the plasma
membrane of AD individuals [48]. β-secretase-1 (BACE-1) contributes to AD as it initially
cleaves the APP protein on the surface of the plasma membrane, forming Aβ. Lipid rafts regulate
BACE1. When LDL lipids become oxidized, this causes the oxidation of the Human
Neuroblastoma Cell Line SHSY-5Y cell glutathione (SHSY-5Y), resulting in lipid rafts [48].
Lipid rafts are essential components of the plasma membrane as they contain sphingolipids and
cholesterol molecules to provide rigidity. This rigidity allows proteins to be segregated in the
membrane and potentially undergo endocytosis via caveolin-mediated endocytosis [49]. The
lipid raft induced formation by oxidized low-density lipoprotein (oxLDL) consequently causes
BACE1 to cleave APP and form Aβ plaques. This research demonstrates that the oxidation of
LDL is an essential contributor to the pathology of AD. When Aβ plaques cluster, they block
neurotransmission at synapses, interrupting the nerve signaling. This contributes to memory loss
seen in AD individuals.
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2.6 Possible Correlate of Cu2+ and in AD Pathology
Macrophages have a surface receptor called scavenger receptor class A (SRA) [50].
OxLDL is composed of 7-ketocholesterol (7-KC), an oxidized cholesterol derivative known as
an oxysterol, which is seen to accumulate inside of macrophages [51]. This causes endoplasmic
reticulum stress, oxidative stress, mitochondrial dysregulation, and cell death [51-54]. LDL can
become oxidized in two ways—ionizing radiation or copper (Cu2+) exposure [55]. Surprisingly,
OxLDL created by ionizing radiation was not able to be identified by SRA on macrophages but
OxLDL created by Cu2+ oxidation was [55]. This has been attributed to hydroperoxide
degradation, which is only exhibited by CU2+ oxidation. Hydroperoxide degradation degrades
lipids and allows cholesterol to be uptaken by macrophages; macrophages are unable to
recognize oxLDL without the breakdown of these lipid hydroperoxide groups [55]. SRA can
interact with oxidized Low-Density Lipoprotein and lead to cholesterol aggregation within foam
cells pertaining to atherosclerosis [56]. Significantly a cohort study, involving 1000 patients’
cases of both AD and related neurodegeneration diseases, reported that up to 77% of AD patients
have atherosclerosis in the circle of Willis [57]. High risks of intracranial atherosclerosis has
been observed in individuals with Alzheimer’s Disease [58]. Having type 2 diabetes increases
the probability of individuals developing atherosclerosis, both of which have been observed to be
present in individuals with AD [58-60]. Not only can copper (Cu2+) contribute to atherosclerosis
[61], a common condition amongst AD, but it can also impact amyloid production and produce
neuroinflammation.

11

Studies have shown that lipid rafts contribute to the formation of amyloid as the amyloid
precursor protein (APP) is exposed to the enzymes (located in the lipid raft) that cleave them
[62, 63]. Thus, the production of amyloid is seen at lipid rafts. Interestingly, when cellular Cu2+
levels are low, Cu2+ affinity for lipid rafts increase and join the amyloid to form a copperamyloid complex; leading to oxidized cholesterol and resulting in the formation of
hydroperoxide (H2O2) [63-65]. Hydroperoxide, as well as lipid peroxidation products,
consequently become abundant in the AD brain. A study set out to explore the effects of H2O2
on microglial cells using a P1 mouse brain as a model. This study discovered that continuous
exposure to H2O2 at low levels created pro-inflammatory cytokines (Macrophage Inflammatory
Protein-1 beta Human Recombinant (MIP-1b) and Macrophage inflammatory Protein-2 (MIP2) ) as well as anti-inflammatory cytokines—granulocyte colony-stimulating factor (G-CSF)
[66]. Thus, suggests that H2O2 can cause neuroinflammation. Interestingly, what makes Bamyloid collect in the brain is the appearance of copper. Studies have shown that when there is
B-amyloid but an absence of copper, the B-amyloid does not build up in the brain but instead, is
released in the circulatory system [67]. Thus, copper is a contributor of AD pathology as it
encourages amyloid to travel to the brain and adversely impact cognitive function by forming
amyloid plaques. Research has also shown that B-amyloid becomes neurotoxic once it attaches
to the cellular plasma membrane; this binding is enhanced by phosphatidylserine [68-71].
However, further research is encouraged to determine the effects that phosphatidylserine plays in
AD.
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Chapter 3: Microbiology Leading to Neuroinflammatory Responses Seen in AD
3.1 Neuroinflammatory Roles of Molecular Receptors
Low-density lipoprotein receptor-related protein 1(LRP1)/apolipoprotein E receptor
(APOER) and Aβ contact gives rise to endocytosis and degradation, which reduces chances for
plaque formation [72]. LRP1 is located on the somatodendritic compartment of microglial
neurons, which includes the cell body and dendrite only, this receptor can perform cell-mediated
endocytosis upon cellular ligands binding to it [73, 74]. Thus, when Aβ plaques bind to
microglia, LRP1 serves as a clearance defense mechanism as microglia remove the pathogenic
aggregates. On the contrary, the microglial receptor, Triggering Receptor Expressed on Myeloid
Cells-2 (TREM-2) is modified in individuals with AD, such that they cannot bind to Aβ plaques
and clear them [75]. Another microglial receptor is the cluster of differentiation 36 (CD36)
receptor; known to initiate a pro-inflammatory response that ruptures the lysosomes [76]. These
lysosomes are important for the prevention of Aβ plaques; they are found in the vesicles that
endocytose the APP molecules and contribute to APP degradation [77]. Additionally, the NLR
family pyrin domain containing-3 (NLRP3) contributes to this pro-inflammatory response as it
releases Interleukin-1-beta (IL-1β) [78]. Mutations in NLRP3 called cryopyrin‐associated
periodic syndromes (CAPS) have been observed in AD individuals; triggering
neuroinflammatory responses by resulting in the ongoing production of IL-1β [79, 80]. High
levels of IL-1β serve as a marker for neuroinflammation, resulting in the recruitment of
leukocytes such as neutrophils, dendritic cells, and monocytes as well as lymphocytes such as
CD4+ and CD8+ T-cells [81]. This activity elicited by IL-1 β results in memory impairment of
the hippocampus, which is one of the earlier structures affected in AD [81]. Furthermore, When
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modified forms of the Low-Density Lipoprotein (LDL), such as oxidized LDL, interact with the
CD36 scavenger receptors on microglia, such interaction is mediated by Toll-like receptor 4
(TLR4) and TLR6 meeting with CD36, inflammatory responses are produced which contribute
to the formation of Aβ plaques [78]. If an oligomer of Aβ contacts the cell surface receptors they
can gain entry to the cell [82]. Upon entry, these oligomers cause the formation of the
Neurotrophin Receptor P75 (P75NTR), and consequently create pores in the plasma membrane
[83, 84]. When this occurs, the Endoplasmic Reticulum (ER) receives stress signals and responds
to initiate a caspase cleavage of tau which causes tau proteins to be cleaved and thus aggregate
together [85]. Thus, so far both caspase cleavage of tau and the previously mentioned posttranslational modification—polyglutamylation—are factors that contribute to tau protein
dysfunction.
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3.2 The Role of Interleukin-3 on Inflammatory Response Regulation- Reduction in Amyloid
Exposure of the brain to Aβ plaques causes neurons of the hippocampus and cortex to die
both in vitro and in vivo [86, 87]. Bcl-2, an important molecule for cell survival, which has antiapoptotic properties, has been shown to be decreased when exposed to Aβ1–40 and Aβ1–
42 plaques; consequently contributing to neurodegeneration [88]. However, Interleukine-3 (IL-3),

a cytokine and colony-stimulating factor (CSF) that allows progenitor cells of all lineages to
mature [89], has been shown to withstand its anti-apoptotic properties despite being exposed to
these same Aβ plaques. Studies have shown that when Aβ plaques, which are neurotoxic, are
exposed to IL-3 the neuronal cell survival rate is increased. In a study, neuronal cells were first
treated with IL-3 at concentrations that increased gradually from 0-10nM for 30 minutes, and
later exposed to 10 μM Aβ1–42 for 24 hours [88]. The study concluded that the highest survival
of neurons was recorded at 10nM, the highest concentration of IL-3. Thus, this shows a positive
correlation between the IL-3 concentrations and cell survival in the presence of neurotoxic
contributors like Aβ plaques. Interestingly in this study, when healthy cortical neurons were
exposed to IL-3, there was no effect, which suggests that IL-3 acts in a neutral way when there is
no harm but positively when exposed to potential neurotoxicity factors. IL-3 can act as a ligand
for cells and regulate the clearance of amyloid plaques via intracellular signaling which modifies
the function of the cell.
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IL-3 has two ligand-specific receptors, the IL-3 ligand-specific receptor A(IL3RA) and
an IL-3 ligand-specific receptor B(IL3RB)—which functions as a signal transducer [90]. When
binding to the surface of a cell, IL-3 utilizes the IL3RA which causes the IL3RB subunit to
transmit an intracellular signal [90]. Recent research has found that astrocytes, one of the most
abundant cells of the central nervous system (CNS) and responsible for functions such as:
shielding neuronal cells from oxidative damage and transmitting neuronal signals [91], produce
the cytokine IL-3 in the brain [92]. These astrocytes secrete IL-3, which acts as a ligand for the
microglial receptor. Microglia have cell surface receptors IL-3Rα that allow for binding to IL-3.
When IL-3 binds, the TREM-2 receptors on the microglia cause the microglia to change shape
and function, at this point the microglia target the AB plaques to clear them [92]. IL-3 helps
neuronal cells survive in the presence of Aβ plaques. This discovery shows the importance of
astrocytes in combating Alzheimer’s disease as they play a direct role in amyloid plaque
clearance. However, this protective effect between the crosstalk of astrocytes and microglia is
lost when there is an excess amount of neuronal death. At this point, the microglia and astrocytes
begin to initiate neuroinflammatory responses [92]. Studies performed on AD individuals with
resilient brains, these brains are barely harmed in the presence of amyloid and neurofibrillary
tangles, suggest that such resiliency may be a response to the absence of neuroinflammatory
responses [93]. These resilient brains have been found to have increased neurotrophic factors like
the – fibroblast growth factor (FGF)— and decreased release of chemokines that result in
microglial activation, in the temporal sulcus (such region becomes affected in the later stages of
AD) [93]. Thus, understanding the fundamental key differences between AD resilient brains and
non-resilient brains can aid in the development of therapeutic agents for AD.
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Figure 4.Depicts the relationship between astrocyte and microglia and their effect on clearing
Aβ plaques.
The presence of IL3RA and IL3RB receptor subunits in cortical neurons were found to
permit the attachment of IL-3 [88]. The hippocampus is made up of three regions called the
Cornu Ammonis 1-3 (CA1, CA2, and CA3). IL-3Rα has been shown to be weakly expressed in
neurons of the CA1 and CA3 regions of the hippocampus and prominently expressed in the
neocortex region [90]. This is important to note because the hippocampus is one of the first
regions of the brain to be affected by AD followed by the cerebral cortex; thus suggesting that
early detection of AD alongside medications that increase IL-3 can potentially halt or decrease
the neurotoxic effects of the AB plaques. However, the neuroprotective effects of IL-3 cannot be
observed without the activation of the Aktα molecule/ Protein Kinase B (PKB), for such to
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happen both Thr-308 and Ser-473 must be phosphorylated in this molecule [88]. A study showed
that when the Aktα molecule became inhibited by LY2940002, an inhibitor of the PI-3 Kinase
pathway (this kinase is activated by IL-3), the neuroprotective effects of IL-3 were not observed.
Thus, for IL-3 to do its job the Aktα molecule must be activated [88].
3.3 The Role of CD4+ T cells on Neurons and Potential Autoantibody as AD Treatment
Previously it was mentioned that IL-1β, which is an inflammatory cytokine, can recruit
CD4+ T-cells [81]. These CD4+ T-cells have surprisingly been found to make neurons
accessible to antibodies. A study revealed that regardless of specificity, T-cells that were called
to the central nervous system (CNS) had the potential to trespass the blood-brain barrier (BBB)
and thus allow for antibody passage [94]. Research has highlighted that in mild Alzheimer’s
Disease CD4+ T-cells but not CD8+ T-cells are most abundantly present [95]. More recent
studies have hinted at the role of autoantibodies towards an array of molecules in AD. T-helper
cells (Th cells) activate B-cells, which differentiate into plasma cells that make autoantibodies.
[96] Normally, immune tolerance allows for low-affinity autoantibodies—self-antibodies— to
target self-antigens such as a dead cell to inhibit the pathway of inflammation [47]. However, in
autoimmune diseases like AD, this immune tolerance is dysregulated and the formation of
pathological autoantibodies, which promote ongoing inflammation responsible for injuring
tissues, become abundant. Autoantibodies against Aβ and Tau proteins have protective roles and
have been classified as having potential immunotherapeutic usages and biomarkers in several
studies [97-102]. A study examined the production of autoantibodies by the B-cells of an AD
patient; these autoantibodies targeted Aβ— thus suggesting potential biomarker usage if found in
circulation [103]. On the other hand, auto-antibodies against ATP synthase have proven to have
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pathogenic roles in AD and can become a potential biomarker [104, 105]. Another study
conducted on a group of individuals with AD utilized an Ig-G antibody affinity-purified
chromatography, a purification method that utilizes Ig-G antibodies to capture proteins, revealed
a positive correlation between the production of Aβ-autoantibodies and cognitive improvement
in these individuals [106]. Studies have shown that in AD patients, the autoantibodies created
against Aβ were mostly unbound and lower in concentration when differentiated from those
produced by healthy individuals. This suggests that if these Aβ-autoantibodies were increased,
perhaps the extermination of plaques will be inversely correlated [96, 97, 107]. However, due to
auto-antibodies exhibiting dual form in circulation—both the unbound and bound-antigen
complex—some studies show no correlation between Aβ-autoantibodies [96, 108, 109] and AD
pathology while others do. Knowingly, researchers decided to investigate the relationship
between bound antigen-Aβ antibody complexes in the CSF and serum of AD patients. Such an
experiment concluded that the level of this complex was elevated in AD individuals as opposed
to the control group [98]. Another study strongly suggests the relationship that Aβautoantibodies have according to the stage of AD— a higher concentration was found in the
mild-moderate phase of AD as opposed to the dementia-severe stage where these levels were
observed to decrease [110]. While the previously mentioned studies relating to Aβautoantibodies suggest a strong potential usage for AD biomarkers and immunotherapy, further
investigations may be needed for affirmation on therapeutic effectiveness.
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Regarding autoantibodies produced against tau, these are less effective at clearing tau in
comparison to Aβ-autoantibodies [111]. In a study, phosphorylated/ unphosphorylated tau
protein in the serum of AD individuals were exposed to tau autoantibodies; it was concluded that
the phosphorylated-tau antibodies of the IgM isotype were elevated in AD patients as opposed to
the control subjects [96, 112]. Thus, it can be observed that autoantibodies are produced as part
of an immunogenic response to clear the offending player, whether it be Aβ or tau. Nonetheless,
further experimentation will be needed to obtain more data on this matter.
3.4 The Role of Microglia on Neurons
It was aforementioned that microglia can change in response to IL-3 and clear Aβ.
Recently, studies have also highlighted the role of microglial cells on the phagocytosis of
neurons. In neurodegenerative diseases like AD, microglia have been observed to phagocytize
live neurons and neuron synapses. In the presence of amyloid-beta, neuron synapse phagocytosis
seems to be induced by the complement system, in which C1q will bind to the neuron synapse
and tag it for phagocytosis by the microglial cell [113]. Another study, which was conducted in
mice who had mutations in their tau protein, amyloid precursor protein, and presenilin-1 (PS1),
demonstrated the death of neurons to be associated with microglial recruitment [114].
Consequently, upon the knock out of the gene C-X3-C Motif Chemokine Receptor 1 (Cx3Cr1)
that had been associated with the recruitment of microglial cells, neuronal loss was observed to
be halted [114]. Other studies have suggested that just the presence of amyloid, before the
formation of amyloid aggregates, is enough for the microglia to phagocytize neurites [115].
Neuron and synapse death was also observed in mice who had a tau protein mutation, and such
was found to be mediated by the complement system. However, upon the introduction of C1q
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antibodies [116], alongside examining the effects of CR3 [117] and C3 [118] knockout, the loss
in neuron and synapse viability was prevented. Thus, microglia and the complement system play
an important role in AD pathology, and perhaps drugs which target the complement system can
be introduced as potential therapeutic agents for AD.

3.5 The Basal Forebrain and Cholinergic System in AD
A cholinergic neuron is able to utilize the neurotransmitter acetylcholine to send
messages to other neurons. Decreased acetylcholine levels have been associated with reduced
learning and memory contributing to AD pathology [119]. Choline acetyltransferase (ChAT) is
an enzyme that exerts its effect upon both choline and acetyl-CoA to produce acetylcholine
[119].
The basal forebrain is responsible for acetylcholine production. The nerve growth factor
(NGF) functions to preserve the life of the cholinergic neurons present in the basal forebrain, as
well as other bodily structures [120]. In AD, NGF levels in the basal forebrain have been found
to decrease along these cholinergic neurons [120]. NGF helps to preserve the phenotypic
integrity of neurons of the peripheral nervous system (PNS) and the functionality of neurons in
the central nervous system (CNS). Neurotrophic factors such as— NGF, Brain-Derived
Neurotrophic Factor (BDNF), and Glial-cell Derived Neurotrophic Factor (GDNF)— help to
foster neuronal and synaptic growth, promote healthy neuronal myelination, and neuronal
viability [121, 122]. BDNF is created when pro-BDNF becomes cleaved by plasmin [123]. There
are cell surface receptors called tropomyosine-related kinase (Trk) receptors to which BDNF
binds. BDNF binds TrKB receptors [124]; this binding plays an important role in axon and
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dendritic growth, promotes healthy synaptic responses, and is an important proliferation factor
[92, 125, 126]. On the other hand, the binding of the immature version of BDNF—pro-BDNF—
with the P75 Neurotrophin receptor (P75NTR) triggers neuronal cell death in microglia and
neurons of the periphery [127]. When there is an offense to the brain via infection or damage,
BDNF acts as a wound healer [128]. It has therefore been noted that dysregulations in BDNF
contribute to the pathology of AD [129]. Some expressions of the P75NTR can be seen on the B
cell lymphocyte, mast cell [130-132], Purkinje neurons in the cerebellum, the cholinergic
neurons of the basal forebrain, as well as motor and sensory neurons of the CNS [84]. Studies
have found that just the overexpression of P75NTR is enough to lead to cell death [133]. This
suggests that both the sole overexpression of P75NTR as well as the pro-BDNF interaction with
the P75NTR, contribute to cell degeneration and neuroinflammatory responses. Thus, finding
therapies that block the P75NTR may prove successful in potentially halting a portion of the AD
pathology.

Figure 5. Demonstrates the interaction of pro-BDNF with P75NTR
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Figure 6. Summary of Molecular Reactions in AD.
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Chapter 4: The Glymphatic System’s Role in Alzheimer’s Disease
4.1 The Roles of Cerebrospinal Fluid and Interstitial Fluid
The glymphatic system is responsible for clearing waste products from the brain, and thus
plays an important role in aiding brain function [134]. To understand the glymphatic system, it is
important to know the roles of the cerebrospinal fluid and interstitial fluid. The brain contains
cerebrospinal fluid (CSF), responsible for acting as a shock absorber in the brain and spinal cord
[135]. CSF is secreted from the ventricles in the brain and fills areas within the brain; The
ventricles are spaces in the brain that contain CSF [135]. CSF contains both chemical and
nutrients, which are extracted from the blood, and are circulated through the CNS [135]. The
removal of toxins from the brain is also seen as one of the primary functions of the CSF [135].
The interstitial fluid (ISF) is responsible for collecting waste that is neurotoxic and combines
such with CSF to flush out these toxins [136, 137]. ISF is found on the parenchymal cells of the
CNS [130, 138]. Certain CSF biomarkers have been observed in higher concentrations in the
brains of AD individuals and serve their purpose in playing a role in AD diagnosis. CSF
biomarkers are accurate because they are used to detect biochemical modifications that have
occurred in the brain. In Alzheimer’s Disease these biomarkers are— Aβ42, phosphorylated-tau
(p-tau) and total-tau (t-tau) [139]. The buildup of these biomarkers is partially caused by the
inability of the CSF to pick them up and clear them from the brain, through processes which will
be discussed in the following sections.
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Figure 7. Demonstrates the movement of cerebrospinal fluid throughout the brain.
All four ventricles of the brain obtain CSF from the choroid plexus [138]. The choroid
plexus is responsible for filtering the arterial blood and performing a sequence of reactions to
transform this blood into CSF. As seen in figure 7, this CSF passes from the lateral ventricles,
ventricles one and two, into the interventricular foramen to reach the third ventricle; proximal to
the thalamus and hypothalamus [138]. The third ventricle not only receives CSF from the lateral
ventricles, but it also makes its own CSF [138]. The CSF from the third ventricle makes its way
down the cerebral aqueduct and into the fourth ventricle [138]. From the fourth ventricle, there
are three branches, the left/right lateral aperture, and the median aperture; the central canal
continues directly from the fourth ventricle [138]. Regardless, these branches along with the
central canal contain CSF from the fourth ventricle. CSF that becomes collected from the fourth
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ventricle is dumped into the subarachnoid space [138]. This CSF is observed to circulate within
the subarachnoid space, but it cannot stay there indefinitely as the CSF contains toxins that need
to be excreted from the brain [140]. For CSF to exit from the brain it must be dumped into
sinuses, such as the superior sagittal sinus, or the perivascular space [138]. The perivascular
space is a space located above the vascular areas, including veins, arteries, and capillaries [140].
CSF from either the perivascular space or sinus is dumped into the perivenous space where it
exits the brain [141].
4.2 Astrocyte Functions in the Glymphatic System

Figure 8. Astrocytes in periarterial space, collecting CSF with their endfeet. This CSF is then
passed onto the perivenous space through a series of processes described in text.
To understand the perivascular space, comprehension of astrocytes must first be set.
Astrocytes have leg-like projections called the astrocyte extensions, and at the end of this leg is
the astrocyte endfeet [142]. The astrocyte endfeet circles around tiny vasculatures, including
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veins, arteries, or capillaries [143]. These astrocyte endfeet wraps around the wall of that
vasculature and perivascular space [143]. The perivascular space can also be named periarterial
or perivenous depending on what vasculature the astrocyte endfeet is wrapped around. In Figure
8, the astrocytes are seen near the blood-brain barrier utilizing their endfeet to wrap around the
arterial wall and the periarterial space (which contains CSF derived from the subarachnoid
space) [143]. Astrocytes play an important role in the structure of the blood-brain barrier (BBB)
as they are responsible for creating the endothelial tight junctions at the BBB [143]. Astrocytes
also function to permit metabolites, energy, and ions present in the blood to diffuse into the brain
[143]. CSF from the periarterial space, picked up from the astrocyte endfeet, is able to diffuse
into the neural tissue and then into the perivenous space of the veins to be exported from the
brain [141]. From the perivenous space, the CSF is drained into the lymphatic system [141]. The
reason for this synchronized transportation of CSF is to pick up toxins such as those produced by
neurons as waste products and toxins like tau protein and amyloid [144]. Interestingly, sleep is
heavily tied to the glymphatic system as this system is more active during sleep than wakefulness
[145]. Thus, it is important to maintain the glymphatic system healthy as it allows for the CSF to
clear out tau and amyloid; getting an adequate amount of sleep each night will improve this
process.
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4.3 The role of Aquaporin-4 (AQP4) in the glymphatic system
A study comparing the glymphatic system in young vs. aged mouse models revealed that
the glymphatic system is compromised in the aging mice population [146]. In this study a
decrease of 80-90% in glymphatic function was observed in the aged mice; including a reduction
in the ability to clear amyloid and the presence of CSF tracers [146]. The importance of genetics
contributing to the glymphatic activity has been noted in animals who lack Aquaporin-4 (AQP4);
preventing the combination of CSF-ISF at the periarterial space and compromising clearance via
the perivascular drainage pathway [147]. AQP4 is a water channel that functions to aid in the
CSF-ISF influx [147] and can be located at the interface between the interstitial and perivascular
space in the brain [134]. In healthy individuals, AQP4 can be located in the astrocytic process
and the perivascular astrocytic endfeet [148, 149]. AQP4 gene deletions in these animals have
been noted to decrease amyloid clearance by 55% and CSF-ISF interchange by 65% [146, 150].
Interestingly, the AQP4 gene is seen to migrate from the astrocyte endfeet to the parenchymal
processes of the astrocyte with age [146]. When this happens, the glymphatic CSF movement
losses both direction and efficiency, compromising waste removal from the brain; such changes
have been prominently observed in individuals with Alzheimer’s Disease [146].
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4.4 Potential T2D ties to the Periarterial Space
One of the contributing factors that allows CSF to move from the perivascular space to
the astrocytic endfeet and eventually to the perivenous space is the pulsation from the artery
caused by the heart contractions which pump blood [146, 151]. It has previously been mentioned
that atherosclerosis is prone to buildup in the circle of Willis in AD patients [57], perhaps this
buildup of plaque in the arteries causes a compromise to arterial pulse pressure reduction
contributing to less CSF being picked up by the astrocytes and less CSF to clear amyloid and tau
proteins. Thus, there might be a connection between T2D inducing atherosclerosis, and
atherosclerosis compromising the flow of blood in the circle of Willis, thus making pulsation
more inefficient and compromising the capacity of the glymphatic system to clear out toxins like
amyloid and tau protein. This compromise in the glymphatic system may take place when
insufficient CSF becomes extracted from the perivascular spaces by the astrocytic endfeet. In
fact, a study has shown that with aging there is an increase in arterial wall stiffness, which has
been shown to reduce the arterial pulsatility [146]; atherosclerosis induces stiffening of the
arterial walls [152]. Some researchers have hypothesized that the perivascular space becomes
enlarged due to this perivascular space becoming clogged, thus reducing the efficiency of the
glymphatic system [153]. Patients with Alzheimer’s Disease may benefit from early testing for
atherosclerosis and preventative medication as there may be a tie between atherosclerosis and the
reduction in glymphatic system efficiency.
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Chapter 5: Alzheimer’s and Lifestyle Influences on Secondary Diseases
5.1 Risk of Type 2 Diabetes Increases in Individuals with Alzheimer’s Disease
Studies have found that having Alzheimer’s Disease increases the chances of developing
type 2 diabetes (T2D) [154]. Impaired fasting glucose (IFG) have been reported almost twice as
high (46%) in individuals with AD than non-AD individuals (24%). A study statistically revealed
that 81% of AD participants had either T2D or IFG [155]. An increase in IFG denotes an
increase in insulin resistance, both of which are related to aging [156]. A major contributing
factor to insulin resistance is the deposits of fatty acids in the bloodstream [157].
Having high fatty acids in the bloodstream leads to insulin resistance, which can cause
diabetes. Type 2 diabetes is most prevalent in AD patients. In adipocytes, the recycling of fatty
acids and glycerol into TAG reduces the fatty acid deposits in the bloodstream [157].
Thiazolidinedione drugs activate Phosphoenolpyruvate Carboxykinase (PEPCK) in the
adipocytes, promoting TAG recycling [157]. The biochemical explanation for this consists of
glyceroneogenesis, both in the adipocyte and the liver. Both the adipocyte and the liver can
convert pyruvate to Dihydroxyacetone Phosphate (DHAP) and isomerase it into Glyceraldehyde3-Phosphate (G3P) [157]. G3P can be converted to phosphatidic acid via two reactions that insert
acyl transferase groups [157]. Phosphatidic acid can be converted to TAG or
glycerophospholipids via phosphatidic acid phosphatase and acetyltransferase addition (promotes
TAG formation) or into glycerophospholipid by the addition of a head group such as choline,
serine, etc. [157]. G3P and fatty acid can become recycled into TAG in both the liver and
adipocyte, reducing free fatty acid in the bloodstream. Type 2 diabetes can be caused by excess
fatty acids released into the bloodstream, which promote insulin resistance. Therefore, the use of
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thiazolidinediones may be a preventative method for the early onset of AD treatment. When the
PEPCK in the adipocyte is underactive or highly activated in the liver, insulin resistance is
promoted, and this increases the chances of diabetes [158]. Since PEPCK in the adipocytes is
inhibited by glucocorticoids and cortisol, this will induce TAG breakdown and result in more
fatty acid availability in the blood, promoting insulin resistance [157].
Researchers have found that cortisol levels appear to be increased at early stages of AD
and suggest that fasting plasma and cerebrospinal fluid (CSF) cortisol levels can be potential preclinical markers of AD [159]. Testing cortisol levels can therefore help in determining preclinical AD. If these levels are high, treatments that reduce cortisol and glucocorticoid levels
alongside thiazolidinediones at this stage can be a potential treatment. This will result in an
activated PEPCK in adipocytes and a decrease in the PEPCK inhibitors. In a recent study,
treatment of insulin was seen to subvert the neurotoxic effects of the AB plaques in a similar way
to treatment with IL-3, thus amplifying neuronal trophic support [88]. A study found that insulin
activates protein kinase B (PKB)/ ATKa molecule in the liver, muscle, and fat cells [160] which
is essential for fostering a functional IL-3 response. This reveals that treating T2D in AD
individuals also helps to ameliorate neuronal responses in Alzheimer’s Disease—IL-3 responses
improve— as well as to promote efficient amyloid clearance.
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5.2 The Effects of Sleep on Alzheimer’s Disease
Research has demonstrated that Aβ plaques in the brain increase with sleep deprivation and thus
result in chronic cerebral Aβ plaque aggregates [161]. The opposite effect is observed in
individuals who extend their sleep as these Aβ plaques decrease in the brain. Additionally, the
accumulation of Aβ plaques results in circadian rhythm dysregulations and sleep pattern
disruptions [162].
Research has also emerged regarding the change in non-REM sleep that allows toxins
like Aβ plaques to be cleared out from the brain—an increase in CSF (cerebrospinal fluid) [163].
In this study, participants’ brain activity was monitored by EEG caps to record their sleep stage;
an MRI machine was used to record CSF activity and blood flow. At the initiation of non-REM
sleep, the neuronal activity in the brain slowed down, and so did the blood flow; this caused CSF
to rush into the brain and act upon toxins, such as Aβ plaques, to wash them away. Another study
found that CSF is able to rush in the brain during sleep in greater concentrations because the
interstitial fluid space in the brain is increased by 60% [164]. The toxins are said to be wiped off
the brain via the lymphatic drainage system which includes the parenchymal glymphatic system
[146]. This glymphatic system is greatly aided by astroglial cells, as they form pores in the
perivascular area, to form a waste disposal system for metabolites and proteins expressing
soluble properties corresponding to the CNS [146]. Studies in transgenic mice have
demonstrated that amyloid is increased during periods of wakefulness [165]. Likewise, in human
studies, the amyloid concentrations in cerebrospinal fluid were higher during wakefulness [166].
Thus, sleep promotes a healthy brain as amyloid plaques are discarded. Additionally, the benefits
of rapid eye movement (REM) sleep have been discussed in several studies, but of particular
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interest is the release of acetylcholine by the basal forebrain during this stage [167]. As
aforementioned, acetylcholine is an important neurotransmitter responsible for learning and
memory, thus, decreased levels of acetylcholine are observed in individuals with AD.
Supplementation studies with melatonin have shown that if taken at adequate times,
melatonin can increase REM sleep and even regulate the circadian rhythm [168] This
information is significant when considering that in the majority of AD individuals, melatonin
levels are decreased and their circadian rhythm is dysregulated [169]. Melatonin supplementation
has proven effective for individuals with AD; both in sleep quality and decreasing the
progression of AD [170]. Sleep duration is also a key player in preventing dementia. In a study
evaluating 7,444 middle-aged women, aged 65-80, those who got six hours or less of sleep per
night were at a 36% more increased risk of developing dementia [171]. So far, it can be
concluded that sleep is important for clearing brain toxins, including amyloid, but both the
duration of sleep and melatonin supplementation are essential contributing factors. These studies
have shown that a potential piece of the AD puzzle would be to get an adequate amount of sleep
and use supplements, if needed, to achieve this goal.
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Therapeutic Agents that Target the Molecular Interactions in AD
Chapter 6: NLRP3 Drug Targets
In Alzheimer’s Disease the presence of mutated NLRP3 causes neuroinflammation. A systemic
review uncovered that in the pre-clinical stage of AD, the inflammatory cytokines IL‐1β and
Caspase-1 were overexpressed [172]. In a study using mouse models with the human APP/PS1
mutations, and thus overexpressing Aβ plaques, administration with NLRP3 inhibitors was seen
to reduce plaque formation and improve cognitive function [173]. While this study proved
successful, additional studies utilizing newly formulated drug compounds have shown similar
results.

6.1 JC124

Figure 9. The chemical structure of the drug JC124; is used to inhibit NLRP3.
The drug JC124 has been formulated as an inhibitor of the NLRP3 inflammasome and tested
on transgenic mice. A 5-month-old female expressing the human APP/PS1 mutation was given an
oral administration of JC124 for a period of 3 months [174]. Results indicated a reduction in Aβ
concentration, reduced neuroinflammation, increased development of neurons in the hippocampus,
improved synaptic efficiency, and heightened memory responses. This study concluded that
inhibitors of the NLRP3 inflammasome are a potential drug target for Alzheimer's Disease [174].
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6.2 Glyburide/ Glibenclamide (GBC)

Figure 10. Demonstrates chemical structure of Glyburide; an indirect inhibitor of NLRP3 and
used for treating type 2 diabetes.
Glyburide/Glibenclamide (GBC) is a sulfonylurea drug used to mainly treat type 2
diabetes [175] However, it can also serve as an indirect inhibitor of the NLRP3 inflammasome.
A study showed that glyburide prevents NLRP3 inflammasome activation in macrophages
derived from the bone marrow [176]. This study points to Glyburide working downstream of the
P2x7 receptor and upstream of the NLRP3 receptor; since this drug was able to block the
operation of caspase-1 and 1L-1β secretion in the presence of just TLR4 signals and
independently of the P2X7receptor [176]. Thus, this makes Glyburide an indirect inhibitor of
NLRP3.
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Figure 11. Depicts the relationship between Px27 and NLRP3 in creating a neuroinflammatory
response. Both have been termed, “partners in crime” [176] in achieving this goal.
Regarding GBC’s role in AD, studies have demonstrated success in reducing memory
lesions and neuroinflammation in the hippocampus of rats eliciting both Alzheimer’s like disease
and type 2 diabetes [177]. The test used for measuring the outcomes included Y-maze and
Morris water-maze tests. It was concluded that GBC can be a potential treatment for AD, but
further research must be done in humans to determine its effectiveness [177]. Interestingly it has
been aforementioned that Alzheimer’s Disease correlates with an increased risk of Type 2
diabetes. The relationship of both diseases, AD and T2D, could potentially be caused by ties to a
dysregulated NLRP3 inflammasome.
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6.3 MCC950

Figure 12. Demonstrates chemical structure of the MCC950 drug; a direct inhibitor of NLRP3.
Studies with APP/PS1 mouse models have shown that the MCC950 drug inhibited the
activation of NLRP3 inflammasome as well as downregulated microglial activity. This promoted
Aβ clearance and ameliorated cognitive function [173].
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Chapter 7: Potential Promising Drugs that clear Aβ plaques via Antibodies

Stage: Prodromal or mild

7.1 Aducanumab

Researchers have formulated a monoclonal antibody drug called Aducanumab, which
serves as a human IgG1 Aβ antibody that reduces brain Aβ plaques aggregates in patients that
have prodromal or mild AD [178]. This drug was approved for the treatment of mild AD by the
Food and Drug Administration (FDA) on 7 June 2021 [179]; it is sold as Aduhelm by Biogen.
It is to note that in a study performed, an increase of amyloid-related imaging
abnormalities related to cerebral edema (ARIA-E) in individuals that expressed Apoɛ4 was
observed [180]. However, these differences were thought to have been based on dosage
administration disparities between the higher and lower dose groups. Nonetheless, it is important
to keep this in mind when considering treatment options.
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7.2 Gantenerumab
Stage: Prodromal-moderate

Gantenerumab is a human monoclonal antibody of the IgG isotype. This antibody binds

to the Aβ epitope at the middle and N-terminal amino acids and N-terminal [181]. Thus, they can
bind both the Aβ oligomers and fibrils. Studies that exposed this antibody to microglial cells and
macrophages found that in order for the antibody to clear Aβ, a concentration of 0.07nm along
with an EC50 of 0.7 nM was required [181, 182]. A cohort study was done on 89 individuals
aged 50-90 with prodromal-moderate AD and detected changes in Aβ using a florbetapir PET
scan [92]. The oral dosage Gantenerumab was uptitrated monthly to 1,200mg for a period of 210 months. Out of these 89 participants, 67 individuals saw a 3.5x greater reduction in amyloid
in comparison to participants being administered 225mg of Gantenerumab for 2 years in the
SCarlet RoAD (SR) study [92]. This suggests that Gantenerumab can be used as a potential AD
drug target.

39

7.3 Donanemab
Stage: Early prodromal, mild-moderate

Donanemab is an antibody that targets Aβ. In a 76-week clinical trial conducted with 257

participants, 131 participants were administered Donanemab while the other 126 received a
placebo. Improvements in cognitive skills and assessment of the daily-life activities were noted
for those on Donanemab [183]. However, this is only a phase II clinical trial, further
experimentation must be performed to assess the effectiveness of Donanemab [183]. In another
study Donanemab was administered intravenously (IV) as a single dose and given to participants
exhibiting mild-moderate stages of AD. The single-dose differed upon five dosing cohorts
ranging from 0.1-10 mg/kg for 12 weeks for the testing group; a placebo group was also selected
[184]. After a 12 week follow up, the dosage was increased from 0.3-10 mg/kg in the testing
group and only administered one day of the month for upto 4 months respective of starting
dosage of cohort group. Another 12 weeks follow-up took place and 3-mg/kg dose of
Donanemab was administered subcutaneously. In another 12 weeks, the results were examined
via a positron emission tomography (PET) scan. The highest of all dosages, 10mg/Kg dose of
Donanemab showed an outstanding amyloid clearance of 40-50%. Furthermore, antibodies were
developed just 3 months following a single IV dose by 90% of participants [184]. Thus,
Donanemab may be an optimal drug treatment to subvert amyloidopathy once it passes clinical
trials.

40

7.4 Lecanemab/BAN2401
Stage: Mild cognitive dementia

Lecanemab is an IgG1 monoclonal antibody observed to target soluble amyloid. A

randomized double-blind clinical study, which included 854 participants with mild AD dementia,
aimed to test the effects of Lecanemab [185]. The first part of the study wanted to find the

dosage amount that would make the treatment at least 90% effective (ED90). Participants were
to be analyzed for 12 months via Bayesian analysis for detectable changes on their Alzheimer's
Disease Composite Score (ADCOMS) regarding ED90. The second part of the study included an
18-month Bayesian analysis on amyloid clearance utilizing a PET scan to measure amyloid
levels. The results indicated that at 12 months, administration of 10-mg/kg biweekly ED90
Lecanemab dose missed the threshold by 80%. In contrast, at 18 months, the administration of
10-mg/kg biweekly Lecanemab dosage was seen to reduce brain amyloid [185]. However,

further investigation will be done as this drug prepares to enter Phase 3 clinical trials to evaluate
true effectiveness.
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7.5 Cocos Nucifera Mitigates AD Symptoms by reducing Aβ plaques
Research conducted on the effects of coconut oil on oxLDL concluded that virgin
coconut oil (VCO) lowered lipid levels in serum and tissues as well as reduced LDL oxidation
due to its polyphenol content [186]. Similar research has demonstrated that the phenolic
compounds of coconut oil prevent the accumulation of amyloid-β peptides, suggesting it may
contribute to mitigating the pathology of AD [187]. Oxidized LDL has proven to promote lipid
raft formation, which fosters BACE1 formation, leading to the formation of Aβ plaques [188].
Thus, coconut oil can be potential use for the mitigation of Aβ plaques.
Research has demonstrated that ketone bodies (KB) can be utilized as brain fuel instead
of glucose; glucose is seen to be less efficiently utilized by the brain in AD individuals as
opposed to ketone bodies [189]. However, plasma ketone body levels must be above the ≤0.2
mM standard concentration seen in metabolically healthy individuals, to deliver KB’s as fuel to
the glucose-deprived regions of the brain [190]. Once KB’s enter the brain their utilization is
almost guaranteed [191]. Studies have shown that administration of medium-chain
triglyceride(MCTG) (such is present in coconut oil (CO)) increased plasma KB levels and was
detected to be metabolized by the brain [192]. Consumption of MCTG has been observed to
elevate ketone bodies and induce hyperketonemia [193].
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Dr. Newport, et.al researched the effects of oral dosage of a ketone monoester (KME)—
(R)-3-hydroxybutyl (R)-3-hydroxybutyrate— upon an APOE ε4-positive AD patient for a period
of 20 months [190]. The researchers also examined the effects of MCTG/CO administration.
Upon gradual augmentation in dosages, reaching 4:3 MCTG/CO, a significant improvement in
activities of daily living, cognitive function, mood, and ability to hold a conversation was noted
in the patient. Administration of KME at 21.5g thrice daily in just the first two days marked an
increase in activities of daily living performance not seen prior to KME administration as well as
the ability to recall basic information. The patient was able to dress without assistance and recite
the alphabet, such behavior was not seen previously. On the third day, the patient was given
28.7g of KME thrice daily for a period of 6-8 weeks. At this point, remarkable improvement in
cognitive function was noted as the patient performed the following activities—not getting lost
in his home, ordering from a menu, conversing about events that took place a week prior,
performing yard work, regaining his sense of humor, etc. Plasma βHB (blood β hydroxybutyrate)
levels were measured upon administration of KME, the results indicated Plasma βHB rose upon
KME administration; cognitive improvement was also noted. The results showed that KME can
induce hyperketonemia (elevated ketone bodies in blood) and become up-taken by the brain to
improve cognition [190]. Throughout the administration of coconut oil in this AD patient, doctor
visits were recorded. The patient was asked to draw a clock upon his visits to assess cognitive
functioning; Figure 13. demonstrates this occurrence.
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Figure 13. Shows the patient's drawings of a clock upon doctor evaluation after coconut oil
intake. From coconut oil drawing by Dr. Mary T Newport, 2008, Coconut Ketones
(https://coconutketones.com). Copyright by Dr. Mary T Newport.
At the beginning of this review, it was discussed that damage to the hippocampus results
in disorientation, loss of new declarative memories, and inability to hold conversations [16]. In
this study the patient observed improvements in all three areas, suggesting that his hippocampal
activity was improving. Thus, coconut oil may be a supplement of interest for the subversion of
AD symptoms and clinical improvement.
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Chapter 8: Tau Protein Tagging agents
8.1 Rhodadine and Thiohydantoin 2

Figure 14. shows the chemical structure of the Rhodanine drug on the left and Thiohydantoin 2
on the right.
A study conducted using inhibition essays demonstrated that Rhodadine, Thiohydantoin 1
(TH1), Thiohydantoin 2 (TH2), bind to tau aggregates [194]. Applying a fluorescent dye on
TH2’s was used as a detection method for neurofibrillary tangles (NFT), as TH2 is attracted to
NFT hotspots. Both Rhodadine and TH2 are encouraged to be used as imaging means for PET
scans and single-photon emission computed tomography (SPECT) scans [194].
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Chapter 9: Inhibitor of Activation Loop in Kinases
9.1 DNL104
Studies have shown that type III receptor-interacting protein kinase 1 (RIPK1) inhibitors are able
to inhibit the activation loop in kinases via hydrophobic interactions [195, 196]. As
aforementioned, the activation loop is essential for recognizing the amino acids—serine,
threonine and tyrosine (serine and threonine are residues in tau protein), thus blocking this site
may prevent the hyperphosphorylation seen in tau. A phase I clinical trial utilizing DNL104, a
RIPK-1 inhibitor, revealed that it guards against neuroinflammation and apoptosis in mouse
models [197]. Additionally, a human trial involving 68 participants, was also conducted. This
trial uncovered that DNL104 is able to selectively cross into the brain and inhibit RIPK-1
without causing central nervous system neurotoxicity [197]. However, it was reported that up to
37.5% of individuals developed liver toxicity. Although DNL104 showed successful inhibition
of RIPK-1 more drugs should be developed and tested to target the same response while
decreasing the side effects. If this is done, a portion of AD pathology will be closer to a
resolution.
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Chapter 10: Activators of PP2A
10.1 Sodium selenate
Stage: Mild-moderate AD

Figure 15. Chemical structure of sodium selenate.
Clinical trials administering this drug for a period of 24 weeks at a dosage of 30mg
resulted in activation of PP2A in patients with AD and had good tolerance amongst participants
[198]. Sodium selenate (Na2SeO4) can activate PP2A in vivo and in vitro; due to anionic
properties, it utilizes its negative charge to activate PP2A [199]. In vivo studies demonstrates
sodium selenate’s affinity for phosphorylated tau; reductions in tau phosphorylation have been
observed both in vivo and in vitro [199]. High dose supplementation with Na2SeO4 was seen to
amplify intake into the CNS and thus suggests that it can have similar effects in the brain upon
dosage modifications [198, 200].
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10.2 Memantine
Stage: Moderate-severe AD

Figure 16. Demonstrates chemical structure of Memantine.
Memantine reduces hyperphosphorylation of tau; but requires the help of I2/SET to
activate PP2A [201]. Dysfunctions in the N-methyl-D-aspartate receptor (NMDAR) lead to
impaired cognition, memory, mood swings, and symptoms involving Behavioral and
Psychological Symptoms of Dementia (BPSD) [202]. BPSD may include anxiety, depression,
hallucinations, insomnia, paranoia, increased suspiciousness, apathy etc [155]. Memantine was
approved by the Food and Drug Administration (FDA) as an agonist of NMDAR in the brain,
thus it is used to reduced symptoms of BPSD in AD individuals [203].
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10.3 Resveratrol

Figure 17. Demonstrates the chemical structure of resveratrol.
Resveratrol reduces the expression of MID1. MID1utilizes the ubiquitin ligase to degrade
the catalytic subunit of PP2A in the MID1-PP2A complex, and therefore resveratrol increases
PP2A activity [204]. This increase in PP2A activity helps with the dephosphorylation of tau
proteins, thus, contributing to a tau pathology resolution.
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Chapter 11: Trichodermamide Drugs
11.1 Trichodermamide

Figure 18. Chemical structure of Trichodermamide C.
Trichodermamide drugs help to inhibit the formation of inflammatory mediators induced
by Aβ and CD36 on microglia [178]. Additional inhibition of inflammatory cytokine IL-6, TNFα, and IL-1β are exerted [178]. These drugs target the hydrophobic tunnel found in the surface
domain of CD36 per molecular docking studies [178]. Thus, Trichodermamide drugs help
protect against neuroinflammation
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Chapter 12: Cholinesterase Inhibitor
12.1 Donepezil
Stage: Mild- Severe AD

Figure 19. Demonstrates chemical structure of Donepezil.
Donepezil is a cholinesterase inhibitor and thereby increases acetylcholine production
near the synaptic cleft [205]. As previously mentioned, acetylcholine production in AD is
decreased; such contributes to memory deficits and the advanced progression of the disease.
Although Donepezil does not change the progression of AD, it offers temporary benefits—
effectiveness present for about 1-3 years—and can improve cognition [206]. Studies in patients
that took this drug for a period of a year demonstrated increased cognitive improvement [207].
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Chapter 13: Muscarinic Acetylcholine Receptor-M1 Agonist
13.1 AF267B/ NGX267

Figure 20. Chemical structure of AF267B.
AF267B is a muscarinic acetylcholine receptor M1 agonist that heightens the expression
of alpha-secretase, previously mentioned in chapter 2.3, which leads to the formation of nonamyloidogenic peptides [208]. The M1 receptor is the most common subtype of muscarine
acetylcholine receptors, and it plays an important role in memory and learning processes
regulation [209]. AF267B activates the M1 receptor; an increase in M1 receptor signaling has
been shown to inhibit GSK-3β whilst upregulating PKC—resulting in a decrease of tau
hyperphosphorylations [208, 210]. It was previously mentioned that AD initiates by affecting the
hippocampus and cortex of the brain subsequently, interestingly, AF267B has been shown to
lower the expression of Aβ42 and tau proteins in these regions of the brain [208]. Other studies
have shown that AF267B also functions as a neurotropic agent and has the ability to work
synergistically with neurotrophins such as NGF and the epidermal growth factor (EGF) [211].
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Discussions and Conclusions
There are puzzle pieces to the cure for Alzheimer’s Disease, and I believed that such
could be found by inspecting the biomolecular interactions and their effect on neuronal cells. The
aim of this literature review was to assess the molecular changes and interactions that contributed
to AD pathology. This study started by providing the potential causes for AD by targeting
immunological responses, neurobiological, and biochemical interactions that advanced to the
disease. Additionally, the relationship between Alzheimer’s Disease and others such as—
atherosclerosis, type 2 diabetes, and sleep dysregulations were explored. I hypothesized that if
Alzheimer’s Disease was examined at the molecular level, a profound understanding could yield
to uncovering treatments that would mitigate its progression. In this review, my hypothesis was
deemed valid as upon examination of AD at each step yielded preventative steps explored
through therapeutic interventions. Treatments for each step of AD were provided such as
antibody therapy, inhibitors, and natural medicine in order to share diversified treatment options.
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Appendix
Figure 13.
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